Patient
SITE015-0117
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2026-01-18
Adverse events
7
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-02 (study day 131); relationship: NOT RELATED
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-27 (study day 126); relationship: NOT RELATED
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 121); relationship: NOT RELATED
Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 118); relationship: RELATED
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 55); relationship: RELATED
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-18 (study day 25); relationship: NOT RELATED
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 19); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.